SynAct Pharma AB (OMXSTO:SYNACT) Financings

SynAct Pharma AB

Financings

RaiseDateIn US dollars
Convertibles of series 2026/2027:2
Closed: SEK 100M raised
Buyers: Fenja Capital II A/S (second tranche of SEK 50 million)
Use of proceeds: Strengthen financial position and support continued clinical development activities and strategic priorities
Nov 18, 2026
Private placement of new shares
Closed: SEK 51.91M raised · SEK 18 a share · Navia Corporate Finance AB
Dealers: Navia Corporate Finance AB (lead)
Buyers: Hunter Capital (major shareholder that has expressed interest in participating); Johannes Schildt (major shareholder who has expressed interest in participating)
Use of proceeds: Increased financial flexibility and extending the cash runway to support post-data partnering discussions
Mar 2, 2026US$5.67M

Read by 6ix AI from the company's releases